

May 10, 2024

To,
National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra-Kurla Complex,
Bandra (East), Mumbai-400 051
Symbol: JLHL

To,
BSE Limited
P. J. Towers,
25th Floor, Dalal Street, Fort
Mumbai 400 001
Code: 543980

Subject: - Outcome of the Board Meeting held on Friday, May 10, 2024

Dear Sir/Madam,

In furtherance to our intimation dated May 02, 2024 & May 07, 2024 this is to inform you that pursuant to Regulations 30, 33 and Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), the Board of Directors of the Company at its Meeting held today, i.e., May 10, 2024, has inter-alia: -

1. Considered and approved the Unaudited Financial Results for the quarter ended March 31, 2024 and Audited Financial Results of the Company for the financial year ended March 31, 2024 (both Standalone and Consolidated), along with the Auditor's Report thereon.

A copy of the said Results along with the Auditors Report issued by the Statutory Auditors of the Company is enclosed herewith as **Annexure – I**.

A declaration on auditor's report with unmodified opinion pursuant to the regulation 33(3)(d) of the SEBI Listing Regulations read with SEBI circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016 is enclosed as **Annexure – II**.

2. Recommendation of a dividend @ 10 % i.e. ₹ 1/- per equity share of face value of Rs.10/- each for the Financial Year 2023-24, subject to approval of shareholders at the ensuing Annual General Meeting. The dividend, if approved by the shareholders in the ensuing Annual General Meeting will be paid on or before 30 days from the date of Annual General Meeting. The Book Closure and Record Date for dividend purpose will be intimated in due course.
3. Considered and approved addition of 75 beds to the existing Indore Hospital and 22 beds to the existing Pune Hospital, Baner.

The requisite disclosures as per Regulation 30 of Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 ('SEBI Circular'), is enclosed as **Annexure – III**.

4. Considered and approved the appointment of M/s. Yogesh Sharma & Co., Practicing Company Secretary as Secretarial Auditor of the Company for conducting Secretarial Audit for Financial Year 2024-25.

Brief Profile of M/s. Yogesh Sharma & Co., in terms of the SEBI Listing Regulations and SEBI Circular is annexed herewith as **Annexure – IV**.

5. Considered and approved the appointment of M/s. V. J. Talati & Co. as Cost Auditor of the Company for conducting Cost Audit for Financial Year 2024-25.

Brief Profile of M/s. V. J. Talati & Co., in terms of the SEBI Listing Regulations and SEBI Circular is annexed herewith as **Annexure – V**.

6. Considered and approved re-appointment of Dr. Ajay Thakker (DIN: - 00120887) as Managing Director of the company for further period of 5 years subject to approval of shareholders of the Company.

Brief Profile of Dr. Ajay Thakker (DIN: - 00120887) in terms of the SEBI Listing Regulations and SEBI Circular, is annexed herewith as **Annexure – VI**.

7. Considered and approved re-appointment of Dr. Ankit Thakker (DIN: - 02874715) as Whole Time Director of the company for further period of 5 years subject to approval of shareholders of the company.

Brief Profile of Dr. Ankit Thakker (DIN: - 02874715) in terms of the SEBI Listing Regulations and SEBI Circular, is annexed herewith as **Annexure – VII**.

Further, details of the Company for the financial year ended March 31, 2024, in reference to SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023, forms part of aforesaid standalone financial results which are enclosed herewith as **Annexure - VIII**.

This information will also be made available on the Company's Website at www.jupiterhospital.com.

The Board Meeting commenced at 03:00 P.M. and concluded at 5.10 P.M.

You are requested to kindly take the afore-mentioned on record and oblige.

Thanking You,

For JUPITER LIFE LINE HOSPITALS LIMITED

Suma Upparatti
Company Secretary & Compliance Officer

Annexure I

Independent Auditor's Report on audit of annual consolidated financial results and review of quarterly financial results

TO THE BOARD OF DIRECTORS OF

JUPITER LIFE LINE HOSPITALS LIMITED

Opinion & Conclusion

We have (a) audited the Consolidated Financial Results for the year ended March 31, 2024 and (b) reviewed the Consolidated Financial Results for the quarter ended March 31, 2024 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying Statement of Consolidated Financial Results for the Quarter and Year Ended March 31, 2024 ("the Statement") of JUPITER LIFE LINE HOSPITALS LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

(a) Opinion on Annual Consolidated Financial Results

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements/financial information of subsidiaries, the Statement:

i. includes the results of the following entities:

Name of the entity	Relationship
Jupiter Life Line Hospitals Limited	Parent
Jupiter Hospital Projects Private Limited	Subsidiary
Medulla Healthcare Private Limited	Subsidiary

ii. is presented in accordance with the requirements of Regulation 33 of the LODR Regulations, as amended; and

iii. gives a true and fair view, in conformity with the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of consolidated total comprehensive income comprising of net profit and other comprehensive income and other financial information of the Group for the year ended March 31, 2024



(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2024

With respect to the Consolidated Financial Results for the quarter ended March 31, 2024, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the quarter ended March 31, 2024, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2024

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Statement

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2024, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2024 that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation

P. Anu



and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Parent Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group

Auditor's Responsibilities

(a) Audit of the Consolidated Financial Results for the year ended March 31, 2024

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the

Q. Anir



consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and jointly controlled entities to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.

We communicate with those charged with governance of the Parent and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the LODR Regulations, as amended, to the extent applicable.

(b) Review of the Consolidated Financial Results for the quarter ended March 31, 2024

We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2024 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all

Q. Anil



significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.

Other Matters

- The Statement includes the results for the quarter ended March 31, 2024 being the balancing figures between the audited figures in respect of the full financial year ended March 31, 2024 and the published unaudited year-to-date figures up to the end of the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations. Our report on the Statement is not modified in respect of this matter.
- We did not audit/review the financial statements/financial information/financial results of one subsidiary: Jupiter Hospital Projects Private Limited included in the statement whose financial statements/financial information/financial results reflect total assets of Rs. 3048.20 million as at March 31, 2024, total revenue of Rs. 453.00 million and Rs. 1593.81 million for the quarter and the year ended March 31, 2024 respectively, total net profit after tax of Rs.21.18 million and Rs. 246.77 million for the quarter and the year ended March 31, 2024 respectively, total comprehensive income of Rs.20.57 million & Rs.246.16 million for the quarter and the year ended March 31, 2024 respectively and net cash outflow of Rs. 29.49 million for the year ended March 31, 2024, as considered in the Statement.

The independent auditors' reports on financial statements/financial results/financial information of this entity have been furnished to us and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this entity, is based solely on the report of such auditor and the procedures performed by us are as stated in paragraph above.

Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

For ASWIN P. MALDE & CO.

Chartered Accountants

Firm's Registration No. 100725W



ASWIN P. MALDE

(Proprietor)

Membership No. 032662

UDIN 24032662BKATYX87T1

Place MUMBAI

Date 10 MAY 2024




JUPITER LIFE LINE HOSPITALS LIMITED
CIN: U85100MH2002PLC137908

AUDITED CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS AT MARCH 31, 2024

₹ In Million

Particulars	Audited	Audited
	As At	As At
	March 31, 2024	March 31, 2023
ASSETS:		
Non-Current Assets:		
(a) Property, plant and equipment	7,155.06	7,189.52
(b) Capital work-in-progress	740.04	291.48
(c) Other intangible assets	21.28	7.48
(d) Financial assets:		
(i) Investments	1.43	1.51
(ii) Other financial assets	788.84	228.92
(e) Other non-current assets	9.03	43.82
	8,715.68	7,762.73
Current Assets:		
(a) Inventories	213.42	189.99
(b) Financial assets:		
(i) Investments	168.66	14.00
(ii) Trade receivables	572.13	456.88
(iii) Cash and cash equivalents	3,012.51	1,344.63
(iv) Loans	5.50	5.25
(c) Other current assets	125.43	81.86
	4,097.65	2,092.61
TOTAL ASSETS	12,813.33	9,855.34
EQUITY AND LIABILITIES:		
Equity:		
Equity share capital	655.66	565.18
Other equity	11,034.72	3,091.67
Minority Interest	(2.99)	(17.75)
	11,687.39	3,639.10
Non-current liabilities:		
(a) Financial liabilities:		
(i) Borrowings	-	4,525.07
(b) Deferred tax liabilities [net]	37.45	369.80
(c) Non current liabilities	30.95	-
	68.40	4,894.87
Current liabilities:		
(a) Financial Liabilities:		
(i) Borrowings	-	161.20
(ii) Trade payables:		
Due to Micro, Small and Medium Enterprises	77.67	55.36
Due to other than Micro, Small and Medium Enterprises	544.73	651.92
(b) Other current liabilities	167.43	180.39
(c) Provisions	245.67	255.96
(d) Current tax liabilities [net]	22.04	16.54
	1,057.54	1,321.37
TOTAL EQUITY & LIABILITIES	12,813.33	9,855.34



JUPITER LIFE LINE HOSPITALS LIMITED

CIN: U85100MH2002PLC137908

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2024

₹ In Million

Particulars	Unaudited	Unaudited	Unaudited	Audited	Audited
	quarter ended 31st March	quarter ended 31st December	quarter ended 31st March	year ended 31st March	year ended 31st March
	2024	2023	2023	2024	2023
Revenue from Operations	2,904.89	2,726.13	2,423.03	10,695.00	8,925.43
Other income	89.51	80.58	34.84	259.82	104.20
TOTAL INCOME	2,994.40	2,806.71	2,457.87	10,954.82	9,029.63
EXPENSES					
Purchases of medical consumables, drugs and surgical items	533.62	483.86	419.20	1,918.09	1,608.57
Changes in inventories of medical consumables, drugs and surgical items	(5.80)	(2.67)	17.48	(23.41)	(36.76)
Employee benefits expense	514.64	500.94	411.70	1,899.36	1,556.36
Finance cost	9.25	10.26	109.37	263.41	422.73
Depreciation and amortisation expense	103.87	106.50	99.76	423.82	385.55
Professional Fees	717.16	680.05	852.02	2,713.58	2,178.77
Other expense	522.49	445.42	206.80	1,805.82	1,605.29
TOTAL EXPENSES	2,395.23	2,224.36	2,116.33	9,000.67	7,720.51
Profit before exceptional items and tax	599.17	582.35	341.54	1,954.15	1,309.12
Exceptional items [net credit/ (charge)]	22.82	(1.52)	(22.04)	-	(22.04)
Profit before tax	621.99	580.83	319.50	1,954.15	1,287.08
Tax expenses					
Current tax	159.27	139.85	155.54	518.87	556.86
Adjustments in respect of current income tax of previous year	3.27	(1.75)	-	1.52	4.32
MAT Credit Entitlement	-	-	(0.01)	-	(47.55)
Deferred tax credit/(charge)	6.80	6.06	6.45	(332.36)	44.40
PROFIT FOR THE PERIOD (A)	452.65	436.67	157.52	1,766.12	729.05
OTHER COMPREHENSIVE INCOME					
Items that will not be reclassified subsequently to profit or loss					
Remeasurement gain/(loss) on defined benefit plans	(9.13)		2.01	(9.13)	2.01
Others				21.55	
OTHER COMPREHENSIVE INCOME FOR THE PERIOD (B)	(9.13)	-	2.01	12.42	2.01
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (A+B)	443.52	436.67	159.53	1,778.54	731.06
Paid up Equity Share Capital (Face value Re. 10 per share)	655.66	655.66	565.18	655.66	565.18
Other Equity	11,031.73	10,587.14	3,073.92	11,031.73	3,073.92
Earnings per equity share (Face value of Re. 10 each)					
Basic (in ₹)	6.49	6.56	2.76	28.65	13.95
Diluted (in ₹)	6.49	6.56	2.84	28.65	12.95



Handwritten signature



Jupiter Life Line Hospitals Limited
Consolidated Statement of Cash Flow for the year ended March 31, 2024

₹ In Million

	For the year ended March 31, 2024	For the year ended March 31, 2023
Cash Flow From Operating Activities		
Profit / (loss) before tax	1,954.15	1,287.08
Adjustments for:		
Share in Profit / (loss) of partnership firms	(30.84)	(17.30)
Depreciation	423.82	385.55
Profit from Sale of Asset	(0.03)	(1.61)
Finance Cost	263.41	422.74
Provision for employee benefit expenses	12.42	(4.12)
Bad debt w/off	13.93	5.54
Expected Credit Loss on trade receivables	8.25	-
Dividend received	(0.14)	(0.09)
Interest Income	(193.87)	(30.67)
Operating profit before working capital changes	2,451.10	2,047.12
Adjustment for (increase)/decrease in operating assets		
Changes in trade and other receivable	(137.45)	(183.72)
Changes in inventories	(23.41)	(36.45)
Changes in other financial and non current assets	(514.69)	5.87
Changes in other current assets	(35.20)	9.12
Adjustment for increase/(decrease) in operating liabilities		
Changes in trade payables	(84.85)	96.12
Changes in current liabilities and provision	(13.46)	(433.39)
Cash Generated from operations	1,642.04	1,504.67
Income tax paid (net of refunds)	(496.83)	(333.00)
Net Cash flow from operating activities (A)	1,145.21	1,171.67
Cash flow from Investing Activities		
Purchase of Property, plant and equipment (including capital work-in-progress, Intangible assets)	(852.95)	(772.43)
Proceeds from sale of property, plant and equipment	1.23	5.35
Investments in Corporates and Partnership Firms	13.02	(211.86)
Investments in mutual fund	(227.49)	-
Proceed from mutual fund	99.11	-
Investments in fixed deposit	(27.43)	(119.53)
Interest Income	235.48	62.68
Dividend received	0.14	0.09
Net Cash flow from Investing Activities (B)	(758.89)	(1,035.70)
Cash Flow from Financing Activities		
Proceed from IPO proceed net of share issue expenses	6,326.27	339.81
Proceed from Long Term Borrowings	1,000.00	486.75
Repayment Long Term Borrowings	(5,563.58)	(31.88)
Proceed from Short Term Borrowing	(161.20)	(146.07)
Dividend paid on equity share	(56.52)	(50.87)
Interest Paid	(263.41)	(422.74)
Net Cash flow from Financing Activities (C)	1,281.56	175.00
Net Increase in Cash and Cash equivalent (A + B + C)	1,667.88	310.98
Opening Balance of Cash and Cash equivalent	1,344.63	1,033.65
Closing Balance of Cash and Cash equivalent	3,012.51	1,344.63
Net Increase in Cash and Cash equivalent	1,667.88	310.98



A. H. H. H.

NOTES TO CONSOLIDATED FINANCIAL RESULTS:

1. These results have been prepared on the basis of the audited consolidated financial statements for the year ended March 31, 2024 and the audited consolidated condensed interim financial statements up to the end of the third quarter, which are prepared in accordance with the Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015. These results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 10, 2024.
2. The statutory auditors have expressed an unmodified audit opinion on consolidated financial results for the year ended March 31, 2024 in terms of SEBI circular CIR/CFD/CMD/56/2016 dated May 27, 2016.
3. As per the Companies Act, 2013 a – “subsidiary company” or “subsidiary”, in relation to any other company (that is to say the holding company), means a company in which the holding company—
 - (i) controls the composition of the Board of Directors; or
 - (ii) exercises or controls more than one-half of the total share capital either at its own or together with one or more of its subsidiary companies.

The entities considered in the Limited Review financial statements are listed below:

Name of the company	Country of Incorporation	Proportion of ownership interest
Jupiter Hospital Projects Private Limited	India	96.56%
Medulla Healthcare Private Limited	India	100.00%

In case of non-body corporate (partnership firms), consolidation is done on the net income basis [share of profit/(loss)], reflected in the head other income in consolidated statement of profit & loss

The non-body corporates which are considered on net income basis are listed below:

Name of the entity	Country of Incorporation	Proportion of ownership interest
Jupiter Pharmacy	India	95%
Katyayini Hospitality	India	95%
Jupiter Gait Lab	India	51%

4. The Financial results have been prepared in accordance with Indian Accounting Standard (Ind-AS) as prescribed under section 133 of Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015 and relevant amendments thereafter.



A handwritten signature or set of initials in blue ink, located to the right of the JLHL stamp.

5. The Group operates in one business and geographical segment i.e., healthcare services in India and all the non-current assets held by the Group are located in India. Hence, there are no additional disclosures to be provided under Ind-AS 108 – Segment information with respect to the single reportable segment, other than those already provided in financial statements. The Company is not required to disclose separately segment reporting as regards Hotel division in financial statement as per Ind AS 108 because its Revenue, Profit & Loss and Assets are not exceeding 10% of Total Revenue, Profit & Loss and Assets of Company.
6. During the year, the Holding Company (JLHL) has completed its Fresh initial public offer ("IPO") of 90,47,469 equity shares of face value of INR 10 each at an issue price of INR 735 per share (including share premium of INR 725 per share). This includes Pre-IPO Placement of 16,73,469 shares. The equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) w.e.f. September 18, 2023.
7. The Board of Directors have recommended a final dividend of ₹ 1/- per equity share of ₹ 10/- each, for the year ended March 31, 2024.
8. Previous period figures have been regrouped/ reclassified to conform the current period classification wherever required.
9. The financial results are available on BSE and NSE websites along with company's website (www.jupiterhospital.com)

For Jupiter Life Line Hospitals Limited

A. Thakker

Dr Ankit A. Thakker
Whole Time Director and CEO
DIN: 02874715
Mumbai
May 10, 2024



Independent Auditor's Report on Audit of Annual Standalone Financial Results and Review of Quarterly Financial Results

TO THE BOARD OF DIRECTORS OF

JUPITER LIFE LINE HOSPITALS LIMITED

Opinion & Conclusion

We have (a) audited the Standalone Financial Results for the year ended March 31, 2024 and (b) reviewed the Standalone Financial Results for the quarter ended March 31, 2024 (refer Other Matters section below), which were subject to limited review by us, both included in the accompanying "Statement of Standalone Financial Results for the Quarter and Year Ended March 31, 2024 ("the Statement") of JUPITER LIFE LINE HOSPITALS LIMITED ("the Company"), being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

(a) Opinion on Annual Standalone Financial Results


In our opinion and to the best of our information and according to the explanations given to us the Standalone Financial Results for the year ended March 31, 2024:

i. are presented in accordance with the requirements of Regulation 33 of the LODR Regulations, 2015, as amended; and

ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the company for the year then ended.

(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2024

With respect to the Standalone Financial Results for the quarter ended March 31, 2024, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2024, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2024


We conducted our audit in accordance with the Standards on Auditing (“SAs”) specified under section 143(10) of the Companies Act, 2013 (“the Act”). Our responsibilities under those Standards are further described in the Auditor’s Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management’s Responsibilities for the Standalone Financial Results

This statement which includes the Standalone Financial Results is the responsibility of the Company’s Board of Directors and has been approved by them for issuance. The Standalone Financial Results for the year ended March 31, 2024 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2024 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company’s financial reporting process.



Auditor's Responsibilities


(a) Audit of the Standalone Financial Results for the year ended March 31, 2024

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2024 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the Company to express an opinion on the Annual Standalone Financial Results.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the



scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Standalone Financial Results for the quarter ended March 31, 2024

We conducted our review of the Standalone Financial Results for the quarter ended March 31, 2024 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of Interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.


Other Matter

The statement includes the results for the quarter ended March 31, 2024 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2024 and the published unaudited year to date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listings Regulations. Our report on the Statement is not modified in respect of this matter.

For ASWIN P. MALDE & CO.

Chartered Accountants

Firm's Registration No. 100725W



ASWIN P. MALDE

(Proprietor)

Membership No. 032662

UDIN 24032662BKATYW7825

Place MUMBAI

Date 10 MAY, 2024



JUPITER LIFE LINE HOSPITALS LIMITED
CIN: U85100MH2002PLC137908

AUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS AT MARCH 31 2024

₹ In Million

Particulars	Audited	Audited
	As At	As At
	March 31, 2024	March 31, 2023
ASSETS:		
Non-Current Assets:		
(a) Property, plant and equipment	4,765.28	4,758.89
(b) Capital work-in-progress	611.04	162.42
(c) Other intangible assets	7.91	5.79
(d) Financial assets:		
(i) Investments	940.34	940.42
(ii) Other financial assets	736.29	178.59
(e) Other non-current assets	2,707.92	838.84
	9,768.78	6,884.95
Current Assets:		
(a) Inventories	167.65	154.94
(b) Financial assets:		
(i) Investments	168.66	14.00
(ii) Trade receivables	463.54	400.25
(iii) Cash and cash equivalents	2,971.95	1,333.07
(iv) Loans	5.50	5.25
(c) Other current assets	59.87	60.90
	3,837.17	1,968.41
TOTAL ASSETS	13,605.95	8,853.36
EQUITY AND LIABILITIES:		
Equity:		
Equity share capital	655.66	565.18
Other equity	11,796.89	4,085.06
	12,452.55	4,650.24
Non-current liabilities:		
(a) Financial liabilities:		
(i) Borrowings	-	2,946.88
(b) Deferred tax liabilities [net]	248.30	250.01
(c) Other non current liabilities	22.08	-
	270.38	3,196.89
Current liabilities:		
(a) Financial Liabilities:		
(i) Borrowings	-	30.54
(ii) Trade payables:		
Due to Micro, Small and Medium Enterprises	60.70	47.72
Due to other than Micro, Small and Medium Enterprises	444.71	576.66
(iii) Other financial liabilities	-	-
(b) Other current liabilities	137.96	154.05
(c) Provisions	217.61	180.72
(d) Current tax liabilities [net]	22.04	16.54
	883.02	1,006.23
TOTAL EQUITY & LIABILITIES	13,605.95	8,853.36



A. Malde



JUPITER LIFE LINE HOSPITALS LIMITED
CIN: U85100MH2002PLC137908
STATEMENT OF AUDITED STADALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2024

₹ In Million

Particulars	Unaudited	Unaudited	Unaudited	Audited	Audited
	quarter ended	quarter ended	quarter ended	year ended	year ended
	31st March	31st December	31st March	31st March	31st March
	2024	2023	2023	2024	2023
Revenue from Operations	2,453.13	2,303.79	2,104.73	9,106.33	7,873.22
Other income	87.41	79.23	65.63	296.28	132.95
TOTAL INCOME	2,540.54	2,383.02	2,170.36	9,402.61	8,006.17
EXPENSES					
Purchases of medical consumables, drugs and surgical items	447.94	398.32	351.24	1,599.96	1,371.30
items	2.19	(2.90)	13.08	(12.71)	(22.30)
Employee benefits expense	425.32	409.37	357.58	1,586.09	1,336.24
Finance costs	9.25	10.10	73.91	186.55	277.12
Depreciation and amortisation expense	74.69	76.52	72.52	305.23	286.08
Professional Fees	583.93	548.53	486.09	2,209.65	1,812.64
Other expense	429.90	379.96	376.50	1,489.63	1,335.02
TOTAL EXPENSES	1,973.22	1,819.90	1,730.92	7,364.40	6,396.10
Profit before exceptional items and tax	567.32	563.12	439.44	2,038.21	1,610.07
Exceptional items [net credit/ (charge)]	22.82	(1.52)	(21.25)	-	(21.25)
Profit before tax	590.14	561.60	418.19	2,038.21	1,588.82
Tax expenses					
Current tax	159.27	139.85	155.54	518.87	556.86
Adjustments in respect of current income tax of previous year	3.27	(1.75)	-	1.52	4.32
MAT Credit Entitlement	-	-	-	-	(47.54)
Deferred tax credit/(charge)	(3.87)	1.15	(4.83)	(1.71)	3.04
PROFIT FOR THE PERIOD (A)	431.47	422.35	267.48	1,519.53	1,072.14
OTHER COMPREHENSIVE INCOME					
Items that will not be reclassified subsequently to profit or loss					
Remeasurement gain/(loss) on defined benefit plans	(8.52)		6.67	(8.52)	6.67
Others				21.55	
OTHER COMPREHENSIVE INCOME FOR THE PERIOD (B)	(8.52)	-	6.67	13.03	6.67
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (A+B)	422.95	422.35	274.15	1,532.56	1,078.81
Paid up Equity Share Capital (Face value Re. 10 per share)	655.66	655.66	565.18	655.66	565.18
Other Equity	11,796.89	11,372.88	4,085.06	11,796.89	4,085.06
Earnings per equity share (Face value of Re. 10 each)					
Basic (in ₹)	6.47	6.48	6.34	24.89	20.58
Diluted (in ₹)	6.47	6.48	4.87	24.89	19.11



A. A. Malde




JUPITER LIFE LINE HOSPITALS LIMITED
STANDALONE STATEMENT OF CASH FLOW FOR THE YEAR ENDED MARCH 31, 2024

₹ In Million

Particulars	For the year ended March 31, 2024	For the year ended March 31, 2023
CASH FLOW FROM OPERATING ACTIVITIES		
Profit / (loss) before tax	2,038.21	1,588.82
Adjustments for:		
Share of Profit in partnership firms	(31.70)	(20.72)
Depreciation and amortisation expenses	305.23	286.08
Profit from Sale of Asset	(0.03)	(1.61)
Finance Cost	186.55	277.12
Provision for employee benefit expenses	13.03	0.53
Bad debt w/off	13.93	5.54
Expected Credit Loss on trade receivables	8.25	-
Dividend received	(0.14)	(0.09)
Interest Income	(232.35)	(60.37)
Operating profit before working capital changes	2,300.98	2,075.30
Adjustment for (increase)/decrease in operating assets		
Trade and other receivable	(85.47)	(129.29)
Inventories	(12.71)	(21.99)
Other financial and non current assets	(514.69)	5.87
Other current assets	0.78	614.93
Adjustment for increase/(decrease) in operating assets		
Trade payables	(118.97)	88.17
Current, non current liabilities and provision	24.82	(459.70)
Cash Generated from operations	1,594.74	2,173.29
Income tax paid (net of refunds)	(496.83)	(333.00)
Net Cash flow from operating activities (A)	1,097.91	1,840.29
CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment (including capital work-in-progress, Intangible assets)	(763.56)	(432.52)
Proceeds from sale of property, plant and equipment	1.23	5.35
Investments in Corporates and Partnership Firms	5.50	(225.08)
investments in mutual fund	(227.49)	-
Proceed from mutual fund	99.11	-
Investments in fixed deposit	(25.13)	(119.53)
Loans/advances to subsidiary	(1,886.96)	(585.25)
Interest Income	232.35	60.37
Dividend received	0.14	0.09
Net Cash flow from Investing Activities (B)	(2,564.81)	(1,296.57)
CASH FLOW FROM FINANCING ACTIVITIES		
Proceed from IPO proceed net of share issue expenses	6,326.27	339.71
Proceed from Long Term Borrowings	1,000.00	-
Repayment Long Term Borrowings	(3,946.88)	(31.88)
Proceed from Short Term Borrowing	(30.54)	(212.09)
Dividend paid on equity share	(56.52)	(50.87)
Interest Paid	(186.55)	(277.12)
Net Cash flow from Financing Activities (C)	3,105.78	(232.25)
Net Increase in Cash and Cash equivalent (A + B + C)	1,638.88	311.48
Opening Balance of Cash and Cash equivalent	1,333.07	1,021.59
Closing Balance of Cash and Cash equivalent	2,971.95	1,333.07
Net Increase in Cash and Cash equivalent	1,638.88	311.48




A. Malde



NOTES TO STANDALONE FINANCIAL RESULTS:

1. These results have been prepared on the basis of the audited standalone financial statements for the year ended March 31, 2024 and the audited standalone condensed interim financial statements up to the end of the third quarter, which are prepared in accordance with the Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015. These results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 10, 2024.
2. The statutory auditors have expressed an unmodified audit opinion on standalone financial results for the year ended March 31, 2024 in terms of SEBI circular CIR/CFD/CMD/56/2016 dated May 27, 2016.
3. The Financial results have been prepared in accordance with Indian Accounting Standard (Ind-AS) as prescribed under section 133 of Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015 and relevant amendments thereafter.
4. The Company operates in one business and geographical segment i.e., healthcare services in India and all the non-current assets held by the Group are located in India. Hence, there are no additional disclosures to be provided under Ind-AS 108 – Segment information with respect to the single reportable segment, other than those already provided in financial statements. The Company is not required to disclose separately segment reporting as regards Hotel division in financial statement as per Ind AS 108 because its Revenue, Profit & Loss and Assets are not exceeding 10% of Total Revenue, Profit & Loss and Assets of Company.
5. During the year, the Company has completed its Fresh initial public offer ("IPO") of 90,47,469 equity shares of face value of INR 10 each at an issue price of INR 735 per share (including share premium of INR 725 per share). This includes Pre-IPO Placement of 16,73,469 shares. The equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) w.e.f. September 18, 2023.
6. The Board of Directors have recommended a final dividend of ₹ 1/- per equity share of ₹ 10/- each, for the year ended March 31, 2024.
7. Previous period figures have been regrouped/ reclassified to conform the current period classification wherever required.
8. The financial results are available on BSE and NSE websites along with company's website (www.jupiterhospital.com)

For Jupiter Life Line Hospitals Limited


Dr Ankit A. Thakker
Whole Time Director and CEO
DIN: 02874715
Mumbai
May 10, 2024



May 10, 2024

To,
National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra-Kurla Complex,
Bandra (East), Mumbai-400 051
Symbol: JLHL

To,
BSE Limited
P. J. Towers,
25th Floor, Dalal Street, Fort
Mumbai 400 001
Code: 543980

Subject: Declaration pursuant to Regulation 33(3)(d) of the Securities & Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Dear Sir/ Madam,

In compliance with Regulation 33(3)(d) of Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016 and SEBI Master Circular No. SEBI/HO/ CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, we hereby declare that, Statutory Auditors of our Company M/s. Aswin P. Malde, Chartered Accountants (FRN: 100725W) have issued an Audit Report with unmodified opinion on Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended 31st March, 2024.

You are requested to kindly take the afore-mentioned on record and oblige.

Thanking you,

For JUPITER LIFE LINE HOSPITALS LIMITED

Mr. Harshad Purani
President Admin And Head - CSR & CFO

Information as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular

Sr. No.	Particulars	Details
1.	Existing Capacity	The Company along with its subsidiary has an existing operational bed capacity of 961 beds as on 31 st March, 2024.
2.	Existing Capacity utilization	The Company's occupancy was 63.8% of its capacity as on 31 st March, 2024.
3.	Proposed Capacity addition	75 beds will be added in the existing Indore Hospital having capacity of 231 beds, post this addition the total bed capacity will be 306 beds. And 22 beds will be added in the existing Pune Hospital, Baner having capacity of 353 beds, post this addition the total bed capacity will be 375 beds.
4.	Period within which the proposed capacity is to be added	The beds will be operationalized by Q4 FY 25
5.	Investment required	The total project cost is approx. ₹ 18 Cr.
6.	Mode of Financing	Internal Accruals & as may be decided by the Board of Directors
7.	Rationale	This facility with added capacity will cater to the increasing demand at Indore for qualitative healthcare services.

Information as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular

Sr. No.	Particulars	Remark
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment of M/s. Yogesh Sharma & Co as Secretarial Auditor of the Company.
2.	Date of appointment	May 10, 2024
3.	Term of appointment	Financial Year 2024-25
4.	Brief Profile	<p>Mr. Yogesh M. Sharma is a Fellow Member of Institute of Company Secretaries of India since more than 15 years. He also holds a Degree in Law. He is also Post Graduate in Commerce and also holds Master's Degree in Finance and Marketing.</p> <p>He has been in Practice since last 15 years providing Legal and Corporate Consultancy to various Listed and Unlisted Companies. He has also appeared in NCLT in various matters relating to Mergers and Amalgamations. His area of Key expertise are Secretarial Audit and Annual Compliance Report under LODR as per SEBI Regulations.</p>

Information as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular

Sr. No.	Particulars	Remark
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment of M/s. V. J. Talati & Co as Cost Auditor of the company.
2.	Date of appointment	May 10, 2024
3.	Term of appointment	Financial Year 2024- 25
4.	Brief Profile	M/s. V. J. Talati & Co., Cost Accountants, Mumbai (Firm Regd. No. R00213) has experience and expertise in Cost Audit over the years. The firm also provides Guidance for Maintenance of Cost Accounting Records as prescribed under the Companies (Cost Records and Audit) Rules, 2014 and certification as regards maintenance of Cost Records by the Company.

Information as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular

Sr. No.	Particulars	Remark
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Re-appointment of Dr. Ajay Thakker (DIN: - 00120887) as Managing Director of the company
2.	Date of Re-appointment	With effective from October 01, 2024
3.	Term of Re-appointment	From October 01, 2024 till September 30, 2029
4.	Brief Profile	He holds a bachelor of medicine and a bachelor of surgery degree from Grant Medical College, University of Bombay and a diploma in medical radio diagnosis, from Topiwala National Medical College, University of Bombay. He is the founder, and Chairman of the Company and is serving as the Managing Director. He has over 40 years of experience in the field of medicine and healthcare. He is currently responsible for the overall management of the Company.
5.	Disclosure of relationships between Directors	Dr. Ajay Thakker is father of Dr. Ankit Thakker
6.	Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/ 2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively	Dr. Ajay Thakker is not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority.

Information as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular

Sr. No.	Particulars	Remark
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Re-appointment of Dr. Ankit Thakker (DIN: - 00120887) as Whole Time Director of the company
2.	Date of Re-appointment	With effective from October 01, 2024
3.	Term of Re-appointment	From October 01, 2024 till September 30, 2029
4.	Brief Profile	He holds a bachelor of medicine and a bachelor of surgery degree from Mahatma Gandhi Mission's Medical College, Navi Mumbai and a masters in management from London School of Economics and Political Science. He has more than a decade of experience in the healthcare sector and has been a Director of the Company since 2016 and is currently responsible for the overall management of the Company. He has been awarded by Financial Express Power List as a FE Visionary Leader for his exemplary contribution to the field of healthcare.
5.	Disclosure of relationships between Directors	Dr. Ankit Thakker is Son of Dr. Ajay Thakker
6.	Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/ 2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively	Dr. Ajay Thakker is not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority.

**Details of the Company in reference to SEBI Circular No. SEBI/HO/DDHS/DDHSRACPODI/P
/CIR/2023/172 dated October 19, 2023, for the financial year ended March 31, 2024**

Sr. No.	Particulars	Details
1.	Outstanding Qualified Borrowings at the start of the financial year (Rs. In Crores)	NIL
2.	Outstanding Qualified Borrowings at the end of the financial year (Rs. In Crores)	NIL
3.	Highest credit rating of the company	NIL
4.	Incremental borrowing done during the year (qualified borrowing) (Rs. In Crores)	NIL
5.	Borrowings by way of issuance of debt securities during the year (Rs. In Crores)	NIL

For JUPITER LIFE LINE HOSPITALS LIMITED

Mr. Harshad Purani
President Admin And Head - CSR & CFO